[Pe-036] 一般演題ポスターセッション（英語）036「筋疾患」

[Pe-036-5] COMET: safety of switching to avalglucosidase alfa (AVA) in late-onset Pompe disease (LOPD)

池田 光伸¹, Jordi Díaz-Manera², Priya S. Kishnani³, Shafeeq Ladha⁴, Patrick Miossec⁵, Nicole Armstrong⁵, Nathan Thibault⁵, Magali Periquet⁵, Swathi Tammireddy⁵, Mazen M. Dimachkie⁶, Benedikt Schoser⁷, on behalf of the COMET Investigator Group (1.サノフィ株式会社, 2.John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK, 3.Duke University Medical Center, Durham, NC, USA, 4.Gregory W. Fulton ALS and Neuromuscular Center, Barrow Neurological Institute, Phoenix, AZ, USA, 5.Sanofi, 6.University of Kansas Medical Center, Department of Neurology, Kansas City, KS, USA, 7.Friedrich-Baur-Institute, Department of Neurology, LMU Klinikum München, München, Germany)